Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🚫 This provider appears on the OIG List of Excluded Individuals/Entities (LEIE)
Exclusion type: 1128a1 · Date: 20251120 · State: CA
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
30,646
Total Claims
$3.0M
Drug Cost
1,993
Beneficiaries
$1,487
Cost/Patient
Risk Score Breakdown 44/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-78%
Opioid rate vs peers
0.5% vs 2.2% avg
+5%
Cost per patient vs peers
$1,487 vs $1,411 avg
+46%
Brand preference vs peers
15.5% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
0.5%
Opioid Rate
149
Opioid Claims
$2,962
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 4,689 claims · $2.2M
Generic: 25,595 claims · $722K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 449 | $251K |
| Sitagliptin Phosphate | 269 | $162K |
| Empagliflozin | 166 | $114K |
| Rivaroxaban | 163 | $96K |
| Dulaglutide | 96 | $95K |
| Semaglutide | 82 | $85K |
| Dapagliflozin Propanediol | 129 | $82K |
| Linagliptin | 122 | $67K |
| Mirabegron | 112 | $60K |
| Linaclotide | 100 | $54K |
| Insulin Glargine,hum.Rec.Anlog | 106 | $54K |
| Lipase/Protease/Amylase | 62 | $53K |
| Vibegron | 82 | $50K |
| Omeprazole/Sodium Bicarbonate | 42 | $47K |
| Icosapent Ethyl | 172 | $47K |
Prescribing Profile
Patient Profile
80
Avg Age
58%
Female
2.09
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About